U.S. Supreme Court Gets Several Briefs Urging Rejection of CMS’s Drug Payment Cuts for 340B Hospitals

Nine friend-of-the-court briefs have been filed urging the U.S. Supreme Court to strike down the CMS rule that imposed a huge cut in 340B hospitals’ Medicare reimbursement for physician administered drugs.

Nine friend-of-the-court briefs have been filed in the nation’s highest court urging rejection of an appeals court’s decision last year that upheld a huge cut in 340B hospitals’ Medicare reimbursement for physician administered drugs.

Please Login

Read More »

Feds Are “Trying to Muscle” Pharma on 340B Contract Pharmacy, Manufacturer Says in Legal Brief

United Therapeutics (UT) says federal health officials are “trying to muscle an obligation” on drug manufacturers to honor 340B contract pharmacy arrangements “that simply is not there."

Federal health officials are “trying to muscle an obligation” on drug manufacturers to honor 340B contract pharmacy arrangements “that simply is not there,” United Therapeutics (UT) said Tuesday in papers filed in federal district court in Washington, D.C.

Read More »

Health Centers Plan to Resubmit 340B Dispute Resolution Petitions

The National Association of Community Health Centers says it intends to resubmit 340B ADR claims against three drug companies. An injunction against ADR proceedings involving one of the companies has kept proceedings against the other two from moving ahead, the federal government said.

The U.S. Health Resources and Service Administration (HRSA) early this month invited community health centers to “resubmit a new” 340B administrative dispute resolution (ADR) petition against drug companies that deny or restrict 340B drug discounts when contract pharmacies are involved,

Read More »

As Frustration Mounts Over 340B Contract Pharmacy Impasse, Arguments in Highly Anticipated AstraZeneca Lawsuit Postponed to Mid-October

Oral arguments previously scheduled for Sept. 14 in drugmaker AstraZeneca’s closely watched 340B contract pharmacy lawsuit against HHS and HRSA have been rescheduled for Oct. 18.

Oral arguments previously scheduled for Sept. 14 in drugmaker AstraZeneca’s 340B contract pharmacy lawsuit against HHS and HRSA have been rescheduled for Oct. 18. The U.S. District Court for the District of Delaware announced the new date for arguments on

Read More »

Hospital Groups Back Feds in United Therapeutics 340B Contract Pharmacy Case

United Therapeutics’ denials of and restrictions on 340B pricing involving contract pharmacies are illegal and jeopardize patient care, six hospital groups have told a federal district judge.

Drug manufacturer United Therapeutics’ (UT) denials of and restrictions on 340B drug discounts when covered entities use contract pharmacies are illegal and jeopardize patient care, six hospital groups have told a federal district judge in Washington, D.C. The groups—American Hospital

Read More »

340B Entities Left Out of BMS’s $75 Million Settlement; Whistleblower Pursues Case Against Lilly

340B covered entities will get none of the $75 million Bristol Myers Squibb is paying to settle claims it underreported its average manufacturer prices (AMPs) in order to underpay Medicaid drug rebates. A whistleblower is pursuing a similar case against Lilly.

340B covered entities will get none of the $75 million Bristol Myers Squibb is paying California, 27 other states, and the federal government to settle claims it underreported its average manufacturer prices (AMPs) in order to underpay Medicaid drug rebates.

Read More »

Recent Supreme Court Ruling Could Affect 340B Dispute Resolution Lawsuits

A recent U.S. Supreme Court decision involving medical device manufacturer Arthrex could influence lawsuits over the 340B program’s administrative dispute resolution (ADR) process.

A U.S. Supreme Court decision in late June about the appointment of federal administrative patent judges (APJs) could influence the outcome of several ongoing lawsuits over the 340B program’s administrative dispute resolution (ADR) process.

 

Please

Read More »

In Strongly Worded Brief in United Therapeutics Case, Feds Defend 340B Contract Pharmacy Actions

Federal officials relied “on sound statutory interpretation and sufficient evidence” when it concluded in May that United Therapeutics (UT) broke the law when it conditioned access to 340B pricing on its products, government lawyers told a federal district judge yesterday.

Federal officials relied “on sound statutory interpretation and sufficient evidence” when it concluded in May that United Therapeutics (UT) broke the law when it conditioned access to 340B pricing on its products, government lawyers told a federal district judge in

Read More »

Feds and AstraZeneca Trade Punches in Drug Maker’s 340B Lawsuit

Drug manufacturer AstraZeneca and the federal government each told a federal district court last Friday why it, and not the other, should prevail in Astra’s lawsuit over the government’s 340B contract pharmacy requirements.

Drug manufacturer AstraZeneca and the federal government each told a federal district court last Friday why it, and not the other, should prevail in Astra’s lawsuit over the government’s 340B contract pharmacy requirements.

Please Login or

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

Sign up for news summaries and alerts from 340B Report